Fichtner-Feigl S - Search Results

1

Pathological complete response in multimodal treatment of esophageal cancer: a retrospective cohort study.

Hipp J, Kuvendjiska J, Hillebrecht HC, Timme-Bronsert S, Fichtner-Feigl S, Hoeppner J, Diener MK. Hipp J, et al. Dis Esophagus. 2023 Jul 3;36(7):doac095. doi: 10.1093/dote/doac095. Dis Esophagus. 2023. PMID: 36572398 Free PMC article.

2

Interleukin 21 impairs tumor immunosurveillance of colitis-associated colorectal cancer.

Kesselring R, Jauch D, Fichtner-Feigl S. Kesselring R, et al. Oncoimmunology. 2012 Jul 1;1(4):537-538. doi: 10.4161/onci.19407. Oncoimmunology. 2012. PMID: 22754778 Free PMC article.

3

Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides.

Fichtner-Feigl S, Fuss IJ, Preiss JC, Strober W, Kitani A. Fichtner-Feigl S, et al. J Clin Invest. 2005 Nov;115(11):3057-71. doi: 10.1172/JCI24792. Epub 2005 Oct 20. J Clin Invest. 2005. PMID: 16239967 Free PMC article.

4

[Hepatocellular Carcinoma: New multimodal therapy concepts].

Schultheiß M, Bettinger D, Fichtner-Feigl S, Thimme R. Schultheiß M, et al. Dtsch Med Wochenschr. 2018 Jun;143(11):815-819. doi: 10.1055/s-0043-124158. Epub 2018 May 28. Dtsch Med Wochenschr. 2018. PMID: 29807383 German.

5

Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.

Moser C, Lang SA, Kainz S, Gaumann A, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK, Stoeltzing O. Moser C, et al. Mol Cancer Ther. 2007 Nov;6(11):2868-78. doi: 10.1158/1535-7163.MCT-07-0410. Mol Cancer Ther. 2007. PMID: 18025273

6

Regulation of AID expression in the immune response.

Crouch EE, Li Z, Takizawa M, Fichtner-Feigl S, Gourzi P, Montaño C, Feigenbaum L, Wilson P, Janz S, Papavasiliou FN, Casellas R. Crouch EE, et al. J Exp Med. 2007 May 14;204(5):1145-56. doi: 10.1084/jem.20061952. Epub 2007 Apr 23. J Exp Med. 2007. PMID: 17452520 Free PMC article.

7

Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2.

Fichtner-Feigl S, Terabe M, Kitani A, Young CA, Fuss I, Geissler EK, Schlitt HJ, Berzofsky JA, Strober W. Fichtner-Feigl S, et al. Cancer Res. 2008 May 1;68(9):3467-75. doi: 10.1158/0008-5472.CAN-07-5301. Cancer Res. 2008. PMID: 18451175 Free PMC article.

8

Clinical and morphological conditions in capsular contracture formed around silicone breast implants.

Prantl L, Schreml S, Fichtner-Feigl S, Pöppl N, Eisenmann-Klein M, Schwarze H, Füchtmeier B. Prantl L, et al. Plast Reconstr Surg. 2007 Jul;120(1):275-284. doi: 10.1097/01.prs.0000264398.85652.9a. Plast Reconstr Surg. 2007. PMID: 17572576

9

Cytokines mediating the induction of chronic colitis and colitis-associated fibrosis.

Fichtner-Feigl S, Strober W, Geissler EK, Schlitt HJ. Fichtner-Feigl S, et al. Mucosal Immunol. 2008 Nov;1 Suppl 1(0 1):S24-7. doi: 10.1038/mi.2008.41. Mucosal Immunol. 2008. PMID: 19079223 Free PMC article. Review.

10

IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis.

Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. Fichtner-Feigl S, et al. Nat Med. 2006 Jan;12(1):99-106. doi: 10.1038/nm1332. Epub 2005 Dec 4. Nat Med. 2006. PMID: 16327802

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

183 results

Search Page